MCID: TBC004
MIFTS: 64

Tobacco Addiction

Categories: Genetic diseases, Mental diseases, Respiratory diseases

Aliases & Classifications for Tobacco Addiction

MalaCards integrated aliases for Tobacco Addiction:

Name: Tobacco Addiction 57
Nicotine Dependence 57 12 29 15 73
Tobacco Use Disorder 12 29 6 44
Tobacco Addiction, Susceptibility to 57 29 6
Nicotine Dependence, Protection Against 57 6
Nicotine Addiction, Protection from 57 13
Smoking Habit 57 55
Cigarette Habituation, Susceptibility to 57
Nicotine Dependence, Susceptibility to 57
Nicotine Addiction, Susceptibility to 57
Addiction, Tobacco, Susceptibility to 40
Smoking Habit, Susceptibility to 57
Cigarette Habituation 57
Nicotine Addiction 57

Characteristics:

OMIM:

57
Inheritance:
genetic factors seem to contribute only in light smokers and heavy smokers


Classifications:



External Ids:

OMIM 57 188890
Disease Ontology 12 DOID:0050742
MeSH 44 D014029
NCIt 50 C54203
SNOMED-CT 68 56294008
UMLS 73 C0028043

Summaries for Tobacco Addiction

MalaCards based summary : Tobacco Addiction, also known as nicotine dependence, is related to major depressive disorder and pathological gambling. An important gene associated with Tobacco Addiction is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Peptide ligand-binding receptors and Nanog in Mammalian ESC Pluripotency. The drugs Nicotine and Sertraline have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Smoking is a practice in which a substance is burned and the resulting smoke breathed in to be tasted... more...

Description from OMIM: 188890

Related Diseases for Tobacco Addiction

Diseases related to Tobacco Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 30.4 SLC6A3 MAOA DRD2 COMT TPH1
2 pathological gambling 30.3 SLC6A3 MAOA DRD2
3 disease of mental health 30.3 SLC6A3 OPRM1 MAOA DRD2 COMT CHRNA4
4 smoking as a quantitative trait locus 3 30.2 CHRNA5 CHRNA3
5 mood disorder 30.2 TPH1 MAOA DRD2 COMT
6 oral leukoplakia 30.2 GSTT1 GSTM1
7 substance abuse 30.1 SLC6A3 MAOA DRD2 COMT
8 bipolar disorder 30.1 TPH1 SLC6A3 MAOA DRD2 COMT CHRNA7
9 anxiety 30.1 TPH1 MAOA COMT
10 alcohol dependence 30.1 TPH1 SLC6A3 OPRM1 MAOA DRD2 COMT
11 attention deficit-hyperactivity disorder 30.0 TPH1 SLC6A3 OPRM1 MAOA DRD2 COMT
12 schizophrenia 30.0 TPH1 SLC6A3 MAOA DRD2 COMT CHRNB2
13 eating disorder 30.0 SLC6A3 DRD2 COMT
14 drug dependence 29.9 OPRM1 DRD2 CHRNB3 CHRNA6 ANKK1
15 mental depression 29.9 TPH1 MAOA COMT
16 personality disorder 29.9 TPH1 SLC6A3 MAOA DRD2 COMT ANKK1
17 conduct disorder 29.8 TPH1 SLC6A3 MAOA DRD2 COMT
18 panic disorder 29.8 TPH1 MAOA COMT
19 substance dependence 29.8 SLC6A3 OPRM1 MAOA GSTM1 DRD2 CHRNB4
20 cocaine dependence 29.7 SLC6A3 OPRM1 DRD2 CHRNB3 CHRNA5 CHRNA3
21 depression 10.5
22 lung cancer 10.3
23 epilepsy, nocturnal frontal lobe, 3 10.3 CHRNB2 CHRNA4
24 autosomal dominant nocturnal frontal lobe epilepsy 2 10.3 CHRNB2 CHRNA4
25 hearing loss, noise-induced 10.3 GSTT1 GSTM1
26 sister chromatid exchange, frequency of 10.3 GSTT1 GSTM1
27 alcohol-induced mental disorder 10.3 SLC6A3 DRD2
28 schizophreniform disorder 10.3 DRD2 COMT
29 isolated cleft lip 10.3 GSTT1 GSTM1
30 toxic encephalopathy 10.3 SLC6A3 GSTT1 GSTM1
31 phobia, specific 10.3 MAOA COMT
32 opioid addiction 10.3 OPRM1 DRD2 COMT
33 avoidant personality disorder 10.3 TPH1 MAOA
34 kleine-levin hibernation syndrome 10.3 TPH1 SLC6A3 COMT
35 polysubstance abuse 10.3 DRD2 COMT
36 alexithymia 10.3 DRD2 COMT ANKK1
37 post-traumatic stress disorder 10.3 MAOA DRD2 COMT
38 gilles de la tourette syndrome 10.3 SLC6A3 DRD2 COMT
39 specific developmental disorder 10.3 SLC6A3 OPRM1 COMT
40 heroin dependence 10.2 OPRM1 DRD2 ANKK1
41 neonatal abstinence syndrome 10.2 OPRM1 COMT
42 brunner syndrome 10.2 TPH1 MAOA COMT
43 opiate dependence 10.2 TPH1 OPRM1 DRD2
44 oppositional defiant disorder 10.2 SLC6A3 MAOA DRD2 COMT
45 tardive dyskinesia 10.2 DRD2 COMT
46 borderline personality disorder 10.2 TPH1 MAOA COMT
47 alcoholic psychosis 10.2 SLC6A3 DRD2
48 somatoform disorder 10.2 TPH1 OPRM1 COMT
49 restless legs syndrome 10.2 SLC6A3 MAOA DRD2
50 epilepsy, idiopathic generalized 10.2 OPRM1 CHRNB2 CHRNA7 CHRNA4

Graphical network of the top 20 diseases related to Tobacco Addiction:



Diseases related to Tobacco Addiction

Symptoms & Phenotypes for Tobacco Addiction

Symptoms via clinical synopsis from OMIM:

57
Misc:
smoking habit


Clinical features from OMIM:

188890

GenomeRNAi Phenotypes related to Tobacco Addiction according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.07 MAOA
2 Decreased viability GR00173-A 10.07 ANKK1
3 Decreased viability GR00221-A-2 10.07 ANKK1
4 Decreased viability GR00221-A-4 10.07 ANKK1
5 Decreased viability GR00240-S-1 10.07 COMT
6 Decreased viability GR00381-A-1 10.07 GSTM1
7 Decreased viability GR00402-S-2 10.07 AKR1B10 ANKK1 CHRNA3 CHRNA4 CHRNA5 CHRNA6
8 no effect GR00402-S-1 9.62 AKR1B10 ANKK1 CHRNA3 CHRNA4 CHRNA5 CHRNA6

MGI Mouse Phenotypes related to Tobacco Addiction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 AKR1B10 CHRNA3 CHRNA4 CHRNA5 CHRNA7 CHRNB2
2 homeostasis/metabolism MP:0005376 9.93 CHRNA3 CHRNA4 CHRNA7 CHRNB2 CHRNB4 COMT
3 integument MP:0010771 9.56 CHRNA4 CHRNB2 CHRNB4 DRD2 GABBR2 OPRM1
4 nervous system MP:0003631 9.44 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Drugs & Therapeutics for Tobacco Addiction

Drugs for Tobacco Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
2
Sertraline Approved Phase 4 79617-96-2 68617
3 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
11 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
12 Serotonin Uptake Inhibitors Phase 4
13 Serotonin Agents Phase 4
14
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
15
Dopamine Approved Phase 2, Phase 3,Phase 1 51-61-6, 62-31-7 681
16
Bupropion Approved Phase 2, Phase 3,Phase 1 34841-39-9, 34911-55-2 444
17
Lobeline Investigational Phase 3,Not Applicable 90-69-7
18 Respiratory System Agents Phase 3
19 Antidepressive Agents, Second-Generation Phase 2, Phase 3,Phase 1
20 Dopamine Uptake Inhibitors Phase 2, Phase 3,Phase 1
21 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Phase 1
22 Dopamine Agents Phase 2, Phase 3,Phase 1
23 Cytochrome P-450 CYP2D6 Inhibitors Phase 2, Phase 3,Phase 1
24
Gemfibrozil Approved Phase 2 25812-30-0 3463
25 Antimetabolites Phase 2
26 Hypolipidemic Agents Phase 2
27 Lipid Regulating Agents Phase 2
28
Memantine Approved, Investigational Phase 1 19982-08-2 4054
29 Antiparkinson Agents Phase 1
30 Excitatory Amino Acids Phase 1
31 Excitatory Amino Acid Antagonists Phase 1

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence Unknown status NCT01038414 Phase 4
2 High Cessation Rates in Smokers Using Personal Vaporizers Completed NCT02124200 Phase 4
3 Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin Terminated NCT02463110 Phase 4 Sertraline;No treatment;Placebo
4 Tobacco Control Among Business Process Outsourcing (BPO) Employees Unknown status NCT00617266 Phase 3
5 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction Completed NCT00392379 Phase 3 Nicotine Lozenges;Placebo lozenge
6 Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence Completed NCT01208935 Phase 2, Phase 3 Nicotine Patch;Nicotine Gum
7 Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking Terminated NCT00248118 Phase 2, Phase 3 Bupropion
8 Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction Completed NCT01876810 Phase 2 Gemfibrozil;Placebo
9 Efficacy and Safety of BP1.4979 in Smoking Cessation Completed NCT01785147 Phase 2 BP1.4979;Placebo
10 Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine Completed NCT00777569 Phase 2 Nicotine free cigarettes;Extra-low nicotine cigarettes;Nicotine Lozenge
11 Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit) Active, not recruiting NCT02823028 Phase 2 NRT
12 Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction Completed NCT01056926 Phase 1 Nicotine patch;Placebo Patch
13 The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1 Completed NCT00136747 Phase 1 Memantine;bupropion;placebo
14 Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment Withdrawn NCT01309685 Phase 1 Varenicline
15 Smoking Cessation Program Among Adolescents in Vocational Training Centers Unknown status NCT00973570 Not Applicable
16 A Photoaging Mobile App Promoting Poster Campaign for Preventing Smoking in Secondary Schools Unknown status NCT02544360 Not Applicable
17 Anodal Transcranial Direct Current Stimulation (tDCS) in the Treatment of Tobacco Addiction Completed NCT01288183 Not Applicable
18 Mindfulness Training for Smoking Cessation Completed NCT01144689 Not Applicable
19 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors Completed NCT02000921 Not Applicable
20 Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia Completed NCT01523730 Not Applicable
21 Effects of Transcranial Direct Current Stimulation on Cigarette Addiction Completed NCT02146014 Not Applicable
22 Trial for Tobacco Cessation With Intensive Advice in Diabetic Patients: the ITADI Project Completed NCT00954967 Not Applicable
23 A Virtual Arm to Stop Smoking Completed NCT00639093 Not Applicable
24 Smoking Cessation for Low-Income Pregnant Women Completed NCT02211430 Not Applicable
25 HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers Completed NCT00491335
26 Effects of Repetitive tDCS on ad Libitum Smoking Behavior: EMA and EEG Study Completed NCT03027687 Not Applicable
27 Evaluating The Efficacy Of A Mind-Body Intervention In Overcoming Opioid Addiction Recruiting NCT03791645 Not Applicable
28 Cluster Randomized Trial of Knowledge Brokering to Integrate Mood and Smoking Cessation in Ontario Primary Care Recruiting NCT03130998 Not Applicable

Search NIH Clinical Center for Tobacco Addiction

Cochrane evidence based reviews: tobacco use disorder

Genetic Tests for Tobacco Addiction

Genetic tests related to Tobacco Addiction:

# Genetic test Affiliating Genes
1 Tobacco Addiction, Susceptibility to 29 CHRNA4 CYP2A6 GABBR2 SLC6A3
2 Nicotine Dependence 29
3 Tobacco Use Disorder 29

Anatomical Context for Tobacco Addiction

MalaCards organs/tissues related to Tobacco Addiction:

41
Testes, Lung, Brain, Endothelial, Heart, Colon, Prostate

Publications for Tobacco Addiction

Articles related to Tobacco Addiction:

(show top 50) (show all 1127)
# Title Authors Year
1
Building the case for comprehensive hospital-based tobacco addiction services: Applying the Ottawa Model to the City of Manchester. ( 29739705 )
2018
2
A randomized clinical trial to evaluate the efficacy of contingency management for treatment of waterpipe tobacco addiction. ( 29569328 )
2018
3
What role does dopamine really play in tobacco addiction? ( 29766605 )
2018
4
Mental health service user and staff perspectives on tobacco addiction and smoking cessation: A meta-synthesis of published qualitative studies. ( 29498459 )
2018
5
Twenty Years of the Cochrane Tobacco Addiction Group: Past, Present, and Future. ( 27798085 )
2018
6
Correlates of nicotine dependence in men with childhood attention-deficit/hyperactivity disorder: a 33-year follow-up. ( 30171588 )
2018
7
Probability and correlates of nicotine dependence among smokers with and without major depressive disorder: Results from the national epidemiology survey on alcohol and related conditions. ( 29350765 )
2018
8
Psychophysical evaluation of contrast sensitivity using Gabor patches in tobacco addiction. ( 30195990 )
2018
9
Is There an Association Between the Degree of Nicotine Dependence and the Motivation to Stop Smoking? ( 30316531 )
2018
10
An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse. ( 30345354 )
2018
11
Drug Addiction: Mechanisms of Nicotine Dependence Unmasked by Gene Editing. ( 30352192 )
2018
12
Association and cis-mQTL analysis of variants in serotonergic genes associated with nicotine dependence in Chinese Han smokers. ( 30405098 )
2018
13
Use of the Fagerström test to assess differences in the degree of nicotine dependence in smokers from five ethnic groups: The HELIUS study. ( 30447512 )
2018
14
Combined genetic influence of the nicotinic receptor gene cluster CHRNA5/A3/B4 on nicotine dependence. ( 30453884 )
2018
15
A Comparison of Gender Differences in Smoking Behaviors, Intention to Quit, and Nicotine Dependence among Thai University Students. ( 30473903 )
2018
16
Prevalence of Nicotine Dependence among Men Aged 21-60 Years in the Rural Field Practice Area of a Tertiary Care Hospital in Tamil Nadu, India. ( 30474006 )
2018
17
Considerations when selecting pharmacotherapy for nicotine dependence. ( 30496692 )
2018
18
Age of tobacco use initiation and association with current use and nicotine dependence among US middle and high school students, 2014-2016. ( 30498008 )
2018
19
Gray matter volumes of insular subregions are not correlated with smoking cessation outcomes but negatively correlated with nicotine dependence severity in chronic smokers. ( 30543846 )
2018
20
Understanding Nicotine Dependence and Addiction Among Young Adults Who Smoke Cigarillos: A Qualitative Study. ( 28184877 )
2018
21
Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. ( 28290528 )
2018
22
Elevated Nicotine Dependence Scores among Electronic Cigarette Users at an Electronic Cigarette Convention. ( 28681280 )
2018
23
Evaluating the mutual pathways among electronic cigarette use, conventional smoking and nicotine dependence. ( 28841780 )
2018
24
Nicotine dependence, internalizing symptoms, mood variability and daily tobacco use among young adult smokers. ( 28943065 )
2018
25
Transitioning from adequate to inadequate sleep duration associated with higher smoking rate and greater nicotine dependence in a population sample. ( 28950118 )
2018
26
Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. ( 28972577 )
2018
27
The Role of Nicotine Dependence in E-Cigarettes' Potential for Smoking Reduction. ( 29065204 )
2018
28
Effects of Negative Affect, Urge to Smoke, and Working Memory Performance (n-back) on Nicotine Dependence. ( 29185837 )
2018
29
Psychometric evaluation of the Patient-Reported Outcomes Measurement Information System (PROMIS) Nicotine Dependence Item Bank for use with electronic cigarettes. ( 29301008 )
2018
30
Nicotine dependence in Croatian male inpatients with schizophrenia. ( 29357830 )
2018
31
Integrative Data Analysis of Gender and Ethnic Measurement Invariance in Nicotine Dependence Symptoms. ( 29396761 )
2018
32
Is the Fagerström test for nicotine dependence invariant across secular trends in smoking? A question for cross-birth cohort analysis of nicotine dependence. ( 29438887 )
2018
33
Not all smokers appear to seek nicotine for the same reasons: implications for preclinical research in nicotine dependence. ( 29480575 )
2018
34
Preclinical evidence for combining the 5-HT2C receptor agonist lorcaserin and varenicline as a treatment for nicotine dependence. ( 29498158 )
2018
35
Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence. ( 29508085 )
2018
36
Sex differences in attaining cigarette smoking and nicotine dependence milestones in novice smokers. ( 29522067 )
2018
37
Analyzing the pathways enriched in genes associated with nicotine dependence in the context of human protein-protein interaction network. ( 29546796 )
2018
38
Associations between opioid and nicotine dependence in nationally representative samples of United States adult daily smokers. ( 29579724 )
2018
39
The Effects of Nicotine and Tobacco use on Brain Reward Function: Interaction with Nicotine Dependence Severity. ( 29584917 )
2018
40
The latent trait of ICD-11 nicotine dependence criteria: Dimensional and categorical phenotypes. ( 29605101 )
2018
41
E-cigarette- specific symptoms of nicotine dependence among Texas adolescents. ( 29627634 )
2018
42
Work Stress and Depressive Symptoms in Fishermen With a Smoking Habit: A Mediator Role of Nicotine Dependence and Possible Moderator Role of Expressive Suppression and Cognitive Reappraisal. ( 29632504 )
2018
43
Differences in nicotine dependence, smoke exposure and consumer characteristics between smokers of machine-injected roll-your-own cigarettes and factory-made cigarettes. ( 29655031 )
2018
44
Association and cis-mQTL analysis of variants in CHRNA3-A5, CHRNA7, CHRNB2, and CHRNB4 in relation to nicotine dependence in a Chinese Han population. ( 29666375 )
2018
45
Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults. ( 29680677 )
2018
46
Cancer Patients Enrolled in a Smoking Cessation Clinical Trial: Characteristics and Correlates of Smoking Rate and Nicotine Dependence. ( 29682394 )
2018
47
Income as a moderator of psychological stress and nicotine dependence among adult smokers. ( 29729584 )
2018
48
Assessing nicotine dependence in adolescent E-cigarette users: The 4-item Patient-Reported Outcomes Measurement Information System (PROMIS) Nicotine Dependence Item Bank for electronic cigarettes. ( 29753155 )
2018
49
The Role of CYP2A6 Genetic Polymorphism in Nicotine Dependence and Tobacco Consumption among Bataknese Male Smokers. ( 29875862 )
2018
50
Brain Structure Alterations in Respect to Tobacco Consumption and Nicotine Dependence: A Comparative Voxel-Based Morphometry Study. ( 29881337 )
2018

Variations for Tobacco Addiction

ClinVar genetic disease variations for Tobacco Addiction:

6 (show top 50) (show all 100)
# Gene Variation Type Significance SNP ID Assembly Location
1 GABBR2 NM_005458.7(GABBR2): c.360A> G (p.Ala120=) single nucleotide variant no interpretation for the single variant rs3750344 GRCh37 Chromosome 9, 101340316: 101340316
2 GABBR2 NM_005458.7(GABBR2): c.360A> G (p.Ala120=) single nucleotide variant no interpretation for the single variant rs3750344 GRCh38 Chromosome 9, 98578034: 98578034
3 GABBR2 GABABR2, HAPLOTYPE, TATA (rs1435252, rs3780422, rs2779562, rs3750344) undetermined variant risk factor
4 GABBR2 GABABR2, HAPLOTYPE, CACA (rs1435252, rs3780422, rs2779562, rs3750344) undetermined variant protective
5 SLC6A3 SLC6A3*9 undetermined variant protective
6 GABBR2 NM_005458.7(GABBR2): c.1236+11101G= single nucleotide variant no interpretation for the single variant rs2491397 GRCh37 Chromosome 9, 101205162: 101205162
7 GABBR2 NM_005458.7(GABBR2): c.1236+11101G= single nucleotide variant no interpretation for the single variant rs2491397 GRCh38 Chromosome 9, 98442880: 98442880
8 GABBR2 NM_005458.7(GABBR2): c.460-23G= single nucleotide variant no interpretation for the single variant rs2184026 GRCh37 Chromosome 9, 101304348: 101304348
9 GABBR2 NM_005458.7(GABBR2): c.460-23G= single nucleotide variant no interpretation for the single variant rs2184026 GRCh38 Chromosome 9, 98542066: 98542066
10 CHRNA4 NM_000744.6(CHRNA4): c.963C> T (p.Ile321=) single nucleotide variant not provided rs121912261 GRCh37 Chromosome 20, 61981800: 61981800
11 CHRNA4 NM_000744.6(CHRNA4): c.963C> T (p.Ile321=) single nucleotide variant not provided rs121912261 GRCh38 Chromosome 20, 63350448: 63350448
12 CHRNA4 NM_000744.6(CHRNA4): c.963C> T (p.Ile321=) single nucleotide variant not provided rs121912261 NCBI36 Chromosome 20, 61452244: 61452244
13 CHRNA4 NM_000744.6(CHRNA4): c.1001C> T (p.Ser334Leu) single nucleotide variant not provided rs121912262 GRCh37 Chromosome 20, 61981762: 61981762
14 CHRNA4 NM_000744.6(CHRNA4): c.1001C> T (p.Ser334Leu) single nucleotide variant not provided rs121912262 GRCh38 Chromosome 20, 63350410: 63350410
15 CHRNA4 NM_000744.6(CHRNA4): c.1002G> A (p.Ser334=) single nucleotide variant not provided rs121912263 GRCh37 Chromosome 20, 61981761: 61981761
16 CHRNA4 NM_000744.6(CHRNA4): c.1002G> A (p.Ser334=) single nucleotide variant not provided rs121912263 GRCh38 Chromosome 20, 63350409: 63350409
17 CHRNA4 NM_000744.6(CHRNA4): c.1054G> A (p.Val352Met) single nucleotide variant not provided rs121912264 GRCh37 Chromosome 20, 61981709: 61981709
18 CHRNA4 NM_000744.6(CHRNA4): c.1054G> A (p.Val352Met) single nucleotide variant not provided rs121912264 GRCh38 Chromosome 20, 63350357: 63350357
19 CHRNA4 NM_000744.6(CHRNA4): c.1066C> T (p.Leu356Phe) single nucleotide variant not provided rs121912265 GRCh37 Chromosome 20, 61981697: 61981697
20 CHRNA4 NM_000744.6(CHRNA4): c.1066C> T (p.Leu356Phe) single nucleotide variant not provided rs121912265 GRCh38 Chromosome 20, 63350345: 63350345
21 CHRNA4 NM_000744.6(CHRNA4): c.1087G> A (p.Val363Met) single nucleotide variant Conflicting interpretations of pathogenicity rs121912266 GRCh37 Chromosome 20, 61981676: 61981676
22 CHRNA4 NM_000744.6(CHRNA4): c.1087G> A (p.Val363Met) single nucleotide variant Conflicting interpretations of pathogenicity rs121912266 GRCh38 Chromosome 20, 63350324: 63350324
23 CHRNA4 NM_000744.6(CHRNA4): c.1109G> A (p.Arg370Gln) single nucleotide variant Likely benign rs121912267 GRCh37 Chromosome 20, 61981654: 61981654
24 CHRNA4 NM_000744.6(CHRNA4): c.1109G> A (p.Arg370Gln) single nucleotide variant Likely benign rs121912267 GRCh38 Chromosome 20, 63350302: 63350302
25 CHRNA4 NM_000744.6(CHRNA4): c.1169G> A (p.Gly390Glu) single nucleotide variant Likely benign rs121912268 GRCh37 Chromosome 20, 61981594: 61981594
26 CHRNA4 NM_000744.6(CHRNA4): c.1169G> A (p.Gly390Glu) single nucleotide variant Likely benign rs121912268 GRCh38 Chromosome 20, 63350242: 63350242
27 CHRNA4 NM_000744.6(CHRNA4): c.1184C> T (p.Thr395Met) single nucleotide variant not provided rs121912269 GRCh37 Chromosome 20, 61981579: 61981579
28 CHRNA4 NM_000744.6(CHRNA4): c.1184C> T (p.Thr395Met) single nucleotide variant not provided rs121912269 GRCh38 Chromosome 20, 63350227: 63350227
29 CHRNA4 NM_000744.6(CHRNA4): c.1200C> T (p.Ser400=) single nucleotide variant not provided rs121912270 GRCh37 Chromosome 20, 61981563: 61981563
30 CHRNA4 NM_000744.6(CHRNA4): c.1200C> T (p.Ser400=) single nucleotide variant not provided rs121912270 GRCh38 Chromosome 20, 63350211: 63350211
31 CHRNA4 NM_000744.6(CHRNA4): c.1224C> T (p.Phe408=) single nucleotide variant not provided rs121912271 GRCh37 Chromosome 20, 61981539: 61981539
32 CHRNA4 NM_000744.6(CHRNA4): c.1224C> T (p.Phe408=) single nucleotide variant not provided rs121912271 GRCh38 Chromosome 20, 63350187: 63350187
33 CHRNA4 NM_000744.6(CHRNA4): c.1228G> A (p.Val410Ile) single nucleotide variant Likely benign rs121912272 GRCh37 Chromosome 20, 61981535: 61981535
34 CHRNA4 NM_000744.6(CHRNA4): c.1228G> A (p.Val410Ile) single nucleotide variant Likely benign rs121912272 GRCh38 Chromosome 20, 63350183: 63350183
35 CHRNA4 NM_000744.6(CHRNA4): c.1265G> A (p.Cys422Tyr) single nucleotide variant Uncertain significance rs121912273 GRCh37 Chromosome 20, 61981498: 61981498
36 CHRNA4 NM_000744.6(CHRNA4): c.1265G> A (p.Cys422Tyr) single nucleotide variant Uncertain significance rs121912273 GRCh38 Chromosome 20, 63350146: 63350146
37 CHRNA4 NM_000744.6(CHRNA4): c.1266C> T (p.Cys422=) single nucleotide variant Uncertain significance rs121912274 GRCh37 Chromosome 20, 61981497: 61981497
38 CHRNA4 NM_000744.6(CHRNA4): c.1266C> T (p.Cys422=) single nucleotide variant Uncertain significance rs121912274 GRCh38 Chromosome 20, 63350145: 63350145
39 CHRNA4 NM_000744.6(CHRNA4): c.1311T> C (p.Ala437=) single nucleotide variant not provided rs121912275 GRCh37 Chromosome 20, 61981452: 61981452
40 CHRNA4 NM_000744.6(CHRNA4): c.1311T> C (p.Ala437=) single nucleotide variant not provided rs121912275 GRCh38 Chromosome 20, 63350100: 63350100
41 CHRNA4 NM_000744.6(CHRNA4): c.1359C> T (p.His453=) single nucleotide variant Benign/Likely benign rs121912276 GRCh37 Chromosome 20, 61981404: 61981404
42 CHRNA4 NM_000744.6(CHRNA4): c.1359C> T (p.His453=) single nucleotide variant Benign/Likely benign rs121912276 GRCh38 Chromosome 20, 63350052: 63350052
43 CHRNA4 NM_000744.6(CHRNA4): c.1373C> T (p.Pro458Leu) single nucleotide variant Uncertain significance rs121912277 GRCh37 Chromosome 20, 61981390: 61981390
44 CHRNA4 NM_000744.6(CHRNA4): c.1373C> T (p.Pro458Leu) single nucleotide variant Uncertain significance rs121912277 GRCh38 Chromosome 20, 63350038: 63350038
45 CHRNA4 NM_000744.6(CHRNA4): c.1402G> A (p.Val468Ile) single nucleotide variant Uncertain significance rs121912278 GRCh37 Chromosome 20, 61981361: 61981361
46 CHRNA4 NM_000744.6(CHRNA4): c.1402G> A (p.Val468Ile) single nucleotide variant Uncertain significance rs121912278 GRCh38 Chromosome 20, 63350009: 63350009
47 CHRNA4 NM_000744.6(CHRNA4): c.1425C> T (p.Gly475=) single nucleotide variant Uncertain significance rs121912279 GRCh37 Chromosome 20, 61981338: 61981338
48 CHRNA4 NM_000744.6(CHRNA4): c.1425C> T (p.Gly475=) single nucleotide variant Uncertain significance rs121912279 GRCh38 Chromosome 20, 63349986: 63349986
49 CHRNA4 NM_000744.6(CHRNA4): c.1460G> A (p.Arg487Gln) single nucleotide variant Benign/Likely benign rs121912280 GRCh37 Chromosome 20, 61981303: 61981303
50 CHRNA4 NM_000744.6(CHRNA4): c.1460G> A (p.Arg487Gln) single nucleotide variant Benign/Likely benign rs121912280 GRCh38 Chromosome 20, 63349951: 63349951

Copy number variations for Tobacco Addiction from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256991 9 99300000 102600000 Gain or loss GPR51 Nicotine dependence

Expression for Tobacco Addiction

Search GEO for disease gene expression data for Tobacco Addiction.

Pathways for Tobacco Addiction

Pathways related to Tobacco Addiction according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
2
Show member pathways
13.13 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
3
Show member pathways
13.06 AKR1B10 COMT CYP2A6 GSTM1 GSTT1 MAOA
4
Show member pathways
12.8 CHRNA3 CHRNA4 CHRNA6 CHRNA7 CHRNB2 CHRNB4
5
Show member pathways
12.64 CHRNA7 CYP2A6 GSTM1 GSTT1 MAOA
6
Show member pathways
12.59 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
7 12.43 COMT GABBR2 OPRM1 TPH1
8 12.01 CHRNA4 CHRNA7 CHRNB2 CHRNB4 MAOA TPH1
9
Show member pathways
11.83 DRD2 MAOA SLC6A3
10
Show member pathways
11.74 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNB2 DRD2
11
Show member pathways
11.6 CYP2A6 GSTM1 GSTT1
12 11.31 CHRNA4 CHRNA6 CHRNA7 CHRNB2
13
Show member pathways
11.15 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
14
Show member pathways
11.09 COMT MAOA SLC6A3
15 11.01 CYP2A6 GSTM1 GSTT1
16
Show member pathways
10.95 COMT MAOA TPH1
17
Show member pathways
10.74 COMT MAOA
18 10.7 COMT MAOA
19
Show member pathways
10.59 AKR1B10 CYP2A6
20
Show member pathways
10.41 CHRNA3 CHRNB4

GO Terms for Tobacco Addiction

Cellular components related to Tobacco Addiction according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.92 CHRNA3 CHRNA4 COMT DRD2 OPRM1
2 postsynaptic membrane GO:0045211 9.85 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
3 integral component of presynaptic membrane GO:0099056 9.8 CHRNA4 CHRNA6 CHRNB2 DRD2 OPRM1 SLC6A3
4 integral component of postsynaptic membrane GO:0099055 9.76 CHRNA6 DRD2 OPRM1 SLC6A3
5 plasma membrane raft GO:0044853 9.67 CHRNA3 CHRNA7 CHRNB2
6 acetylcholine-gated channel complex GO:0005892 9.56 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
7 cholinergic synapse GO:0098981 9.54 CHRNB2 CHRNB4
8 dopaminergic synapse GO:0098691 9.17 CHRNA4 CHRNA5 CHRNA6 CHRNB2 CHRNB3 DRD2
9 membrane GO:0016020 10.42 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
10 integral component of membrane GO:0016021 10.35 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
11 plasma membrane GO:0005886 10.32 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
12 integral component of plasma membrane GO:0005887 10.15 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
13 cell junction GO:0030054 10.09 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
14 synapse GO:0045202 10.06 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
15 neuron projection GO:0043005 10 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Biological processes related to Tobacco Addiction according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 regulation of synaptic vesicle exocytosis GO:2000300 9.97 CHRNA4 CHRNA5 CHRNA6 CHRNB2 CHRNB3 DRD2
2 excitatory postsynaptic potential GO:0060079 9.96 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
3 response to hypoxia GO:0001666 9.92 CHRNA4 CHRNA7 CHRNB2 DRD2
4 response to ethanol GO:0045471 9.91 CHRNB2 DRD2 OPRM1 SLC6A3
5 regulation of postsynaptic membrane potential GO:0060078 9.91 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2 CHRNB3
6 response to cocaine GO:0042220 9.88 CHRNB2 DRD2 OPRM1 SLC6A3
7 neuromuscular synaptic transmission GO:0007274 9.87 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNB2 CHRNB3
8 response to nicotine GO:0035094 9.85 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
9 acetylcholine receptor signaling pathway GO:0095500 9.83 CHRNA3 CHRNA4 CHRNA7 CHRNB2
10 sensory perception of pain GO:0019233 9.8 CHRNA4 CHRNB2 OPRM1
11 behavioral response to nicotine GO:0035095 9.8 CHRNA3 CHRNA4 CHRNA5 CHRNB2 CHRNB4
12 cognition GO:0050890 9.79 CHRNA4 CHRNA7 CHRNB2
13 regulation of dopamine secretion GO:0014059 9.79 CHRNA4 CHRNA6 CHRNB2
14 membrane depolarization GO:0051899 9.77 CHRNA4 CHRNA6 CHRNB2
15 action potential GO:0001508 9.77 CHRNA4 CHRNB2 CHRNB4
16 dopamine catabolic process GO:0042420 9.76 COMT MAOA SLC6A3
17 response to acetylcholine GO:1905144 9.72 CHRNA3 CHRNA7 CHRNB2
18 synaptic transmission involved in micturition GO:0060084 9.71 CHRNA3 CHRNB2 CHRNB4
19 glutathione derivative biosynthetic process GO:1901687 9.68 GSTM1 GSTT1
20 regulation of smooth muscle contraction GO:0006940 9.68 CHRNA3 CHRNB4
21 negative regulation of adenylate cyclase activity GO:0007194 9.68 GABBR2 OPRM1
22 positive regulation of long-term synaptic potentiation GO:1900273 9.67 CHRNA7 DRD2
23 response to iron ion GO:0010039 9.67 DRD2 SLC6A3
24 smooth muscle contraction GO:0006939 9.67 CHRNB2 CHRNB4
25 dopamine metabolic process GO:0042417 9.66 COMT DRD2
26 prepulse inhibition GO:0060134 9.66 DRD2 SLC6A3
27 catecholamine metabolic process GO:0006584 9.65 COMT MAOA
28 neurotransmitter catabolic process GO:0042135 9.65 COMT MAOA
29 regulation of dopamine metabolic process GO:0042053 9.65 CHRNB2 SLC6A3
30 short-term memory GO:0007614 9.64 CHRNA7 COMT
31 adenohypophysis development GO:0021984 9.64 DRD2 SLC6A3
32 behavioral response to ethanol GO:0048149 9.63 DRD2 OPRM1
33 nervous system process GO:0050877 9.56 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
34 synaptic transmission, cholinergic GO:0007271 9.23 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
35 signal transduction GO:0007165 10.31 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
36 ion transport GO:0006811 10.16 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
37 ion transmembrane transport GO:0034220 10.11 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
38 chemical synaptic transmission GO:0007268 10.11 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
39 regulation of membrane potential GO:0042391 10.03 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
40 locomotory behavior GO:0007626 10.02 CHRNA3 CHRNA4 CHRNB2 CHRNB4 DRD2 OPRM1

Molecular functions related to Tobacco Addiction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.97 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
2 acetylcholine binding GO:0042166 9.92 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
3 acetylcholine receptor activity GO:0015464 9.86 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
4 acetylcholine-gated cation-selective channel activity GO:0022848 9.76 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
5 transmembrane signaling receptor activity GO:0004888 9.73 CHRNA4 CHRNA7 CHRNB2 CHRNB4
6 drug binding GO:0008144 9.71 CHRNB2 CHRNB4 DRD2 SLC6A3
7 extracellular ligand-gated ion channel activity GO:0005230 9.56 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2
8 dopamine binding GO:0035240 9.46 DRD2 SLC6A3
9 ligand-gated ion channel activity GO:0015276 9.23 CHRNA3 CHRNA4 CHRNA5 CHRNA6 CHRNA7 CHRNB2

Sources for Tobacco Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....